As Washington lawmakers continue to scrutinize the pharmaceutical industry over drug pricing, the "Fast Money" traders discuss if there is opportunity in the space and where else they should make plays in the market.

Trader Guy Adami said he likes the . He said he believes there is still room for the ETF to trade higher. The stock is up over 15 percent in the last 12 months.